We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Provention Bio Inc | NASDAQ:PRVB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.98 | 25.04 | 24.90 | 0 | 01:00:00 |
By Chris Wack
Provention Bio Inc. shares were up 13% to $3.85 Friday after the company said it intends to resubmit the teplizumab biologics license application for the delay of clinical type 1 diabetes in at-risk individuals following its Type B pre-BLA resubmission meeting with the U.S. Food and Drug Administration.
The company said the purpose of the Type B pre-BLA resubmission meeting was to discuss FDA feedback and obtain agreement on Provention's proposed clinical pharmacology data package.
In preliminary meeting comments, the FDA noted that the data package presented doesn't adequately support pharmacokinetic comparability because predicted primary PK parameters are indicative of a lower exposure.
To address this concern, the FDA proposed, and the company agreed, to use PK modeling to adjust the 14-day dosing regimen for the planned commercial product to match the exposure of clinical material used in prior clinical trials by ensuring that the 90% confidence intervals for relevant PK parameters fall within the target 80% to 125% range. On this basis, the FDA agreed that Provention could proceed to resubmit the BLA.
Under applicable FDA guidelines, the FDA has 30 days to review the BLA resubmission, determine whether it is complete and acceptable for review, and provide the due date for action. Under BTD and priority review designation, the FDA's guidance is to complete its review within six months of the BLA resubmission date.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 28, 2022 10:23 ET (15:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Provention Bio Chart |
1 Month Provention Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions